SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES

被引：1

作者：

Poddubnyy, D. ^{[1
]}

Gensler, L. S. ^{[2
]}

Mease, P. J. ^{[3
]}

Orbai, A. M. ^{[4
]}

Warren, R. B. ^{[5
]}

Ink, B. ^{[6
]}

Massow, U. ^{[7
]}

Assudani, D. ^{[6
]}

Fleurinck, C. ^{[8
]}

Shende, V. ^{[6
]}

Smith, J. ^{[6
]}

Peterson, L. ^{[9
]}

White, K. ^{[6
]}

Landewe, R. B. M. ^{[10
,11
]}

机构：

[1] Charite Univ Med Berlin, Dept Gastroenterol Infect Dis & Rheumatol, Berlin, Germany

[2] Univ Calif San Francisco, Dept Med Rheumatol, San Francisco, CA USA

[3] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[4] Univ Washington, Seattle, WA USA

[5] Johns Hopkins Univ, Div Rheumatol, Sch Med, Baltimore, MD USA

[6] Univ Manchester, Salford Royal NHS Fdn Trust, Manchester NIHR Biomed Res Ctr, Dermatol Ctr, Manchester, England

[7] UCB Pharma, Slough, England

[8] UCB Pharma, Monheim, Germany

[9] UCB Pharma, Morrisville, NY USA

[10] Amsterdam Rheumatol & Clin Immunol Ctr, Amsterdam, Netherlands

[11] Zuyderland MC, Heerlen, Netherlands

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

Safety; Psoriatic arthritis; Spondyloarthritis; 24-WEEK EFFICACY; MULTICENTER;

D O I：

10.1136/annrheumdis-2023-eular.2758

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AB0938

引用

页码：1686 / 1687

页数：2

共 5 条

[1] Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts [J].

Boel, Anne ;

Molto, Anna ;

van der Heijde, Desiree ;

Ciurea, Adrian ;

Dougados, Maxime ;

Gensler, Lianne S. ;

Santos, Maria-Jose ;

De Miguel, Eugenio ;

Poddubnyy, Denis ;

Rudwaleit, Martin ;

van Tubergen, Astrid ;

van Gaalen, Floris A. ;

Ramiro, Sofia .

ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (11) :1545-1549

[2] BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY [J].

Deodhar, A. ;

Van der Heijde, D. ;

Gensler, L. S. ;

Xu, H. ;

Gaffney, K. ;

Dobashi, H. ;

Maksymowych, W. P. ;

Rudwaleit, M. ;

Magrey, M. ;

Elewaut, D. ;

Oortgiesen, M. ;

Fleurinck, C. ;

Ellis, A. ;

Vaux, T. ;

Smith, J. ;

Baraliakos, X. .

ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 :772-773

[3] BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY [J].

McInnes, I. ;

Coates, L. ;

Landewe, R. B. M. ;

Mease, P. J. ;

Ritchlin, C. T. ;

Tanaka, Y. ;

Asahina, A. ;

Gossec, L. ;

Gottlieb, A. B. ;

Warren, R. B. ;

Ink, B. ;

Assudani, D. ;

Coarse, J. ;

Bajracharya, R. ;

Merola, J. F. .

ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 :206-207

[4] BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY [J].

Merola, J. F. ;

McInnes, I. ;

Ritchlin, C. T. ;

Mease, P. J. ;

Landewe, R. B. M. ;

Asahina, A. ;

Tanaka, Y. ;

Warren, R. B. ;

Gossec, L. ;

Gladman, D. D. ;

Behrens, F. ;

Ink, B. ;

Assudani, D. ;

Bajracharya, R. ;

Coarse, J. ;

Coates, L. .

ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 :167-169

[5] BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY [J].

Van der Heijde, D. ;

Baraliakos, X. ;

Dougados, M. ;

Brown, M. ;

Poddubnyy, D. ;

Van den Bosch, F. ;

Haroon, N. ;

Xu, H. ;

Tomita, T. ;

Gensler, L. S. ;

Oortgiesen, M. ;

Fleurinck, C. ;

Vaux, T. ;

Marten, A. ;

Deodhar, A. .

ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 :12-13

← 1 →